Hostname: page-component-cd9895bd7-dzt6s Total loading time: 0 Render date: 2024-12-25T04:56:34.671Z Has data issue: false hasContentIssue false
  • English
  • Français

Arguments against the biomarker-driven diagnosis of AD

Published online by Cambridge University Press:  13 November 2012

Helen F.K. Chiu  and
Henry Brodaty
Helen F.K. Chiu
Affiliation:
Department of Psychiatry, Faculty of Medicine, The Chinese University of Hong Kong SAR, China Email: [email protected]
Henry Brodaty
Affiliation:
Dementia Collaborative Research Center, School of Psychiatry, Faculty of Medicine, University of New South Wales, Sydney, Australia
Get access

Extract

Impressive developments in the biomarker diagnosis of Alzheimer's disease (AD and pre-symptomatic states, using cerebrospinal fluid (CSF), positron emission tomography (PET), magnetic resonance imaging (MRI), and proteomics, have been at the forefront of research in the last decade. With the publication of the criteria of Dubois et al. (2007) and the revised National Institute on Aging and Alzheimer's Association (NIA–AA) criteria for the diagnosis of AD (Jack et al., 2011), this has further ignited the interest and enthusiasm for researchers and clinicians in the field. In some of the major conferences on dementia in recent years, the topic of the biomarker-driven diagnosis of AD has dominated the research agenda. But many questions arise as to how this research will translate into practice. Here, we would like to put forward our arguments against a biomarker-driven diagnosis of AD, and we would caution that very early diagnosis of AD may not result in better care of the subjects.

Type
FOR DEBATE: IS VERY EARLY DIAGNOSIS OF AD USING THE NEW CRITERIA BENEFICIAL FOR PATIENTS?
Information
International Psychogeriatrics , Volume 25 , Issue 2 , February 2013 , pp. 177 - 181
Copyright
Copyright © International Psychogeriatric Association 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)